ArticleReproductive biology and endocrinology : RB&E2025
Colony-stimulating factor-1 as a potential therapeutic target in asthenozoospermia.
Article in Reproductive biology and endocrinology : RB&E, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundAsthenozoospermia (AZS), a common cause of male infertility, is characterized by significantly reduced sperm motility, though its precise etiology remains unclear. Recent research highlights seminal plasma proteins' critical role in regulating sperm function. Colony-stimulating factor 1 (CSF-1), an essential cytokine for immune regulation and cell proliferation, has been implicated in sperm functional regulation, spermatogenesis, and maturation.
methodsSeminal plasma samples from healthy men and AZS patients were collected using density-gradient centrifugation. Proteomics-based data-independent acquisition (DIA) identified four differentially expressed proteins: CD40, CSF-1, MCP-1, and IL-20. To provide an exploratory, proof-of-concept verification before large-scale validation. Subsequent validation in an independent small cohort confirmed a robust association between elevated seminal plasma CSF-1 levels and AZS. An in vitro sperm culture system assessed CSF-1's function of sperm from AZS patients were treated with the CSF-1 inhibitor Pexidartinib, while recombinant CSF-1 was supplemented in sperm from healthy donors.
resultsPexidartinib treatment significantly increased sperm motility in AZS patients, whereas recombinant CSF-1 supplementation significantly reduced motility in healthy donor sperm. CSF-1 inhibition elevated intracellular ATP levels, suggesting disruption of mitochondrial energy metabolism as the mechanism for impaired motility. Proteomic profiling and functional assays demonstrated that seminal plasma CSF-1 induces mitochondrial dysfunction, thereby decreasing sperm motility.
conclusionSeminal-plasma CSF-1 is a potential pathogenic factor in AZS. Its overexpression suppresses sperm motility by impairing mitochondrial energy metabolism. CSF-1 represents both a diagnostic biomarker and a promising therapeutic target (e.g., via Pexidartinib) for the clinical management of AZS. These findings provide a foundation for novel diagnostic and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.